A Covalent Allosteric Molecular Glue Suppresses NRF2-Dependent Cancer Growth.
Nilotpal Roy, Tine Wyseure, I-Chung Lo...
https://pubmed.ncbi.nlm.nih.gov/41417010/Actively Recruiting
Led by Vividion Therapeutics, Inc. · Updated on 2026-05-08
290
Participants Needed
26
Research Sites
25 weeks
Total Duration
Researchers are evaluating VVD-130037, a Kelch-like ECH Associated Protein 1 KEAP1 activator, in adults with advanced solid tumors in a first-in-human study. The study aims to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and early anti-tumor activity of VVD-130037, both alone and combined with other cancer treatments. This is an open-label, phase 1 trial sponsored by Vividion Therapeutics, Inc., focusing on patients whose cancer has progressed despite prior standard therapies. Participants receive escalating doses of VVD-130037 orally once or twice daily in 21- or 28-day treatment cycles. In Part 1 dose escalation, VVD-130037 is tested alone and combined with intravenous docetaxel, paclitaxel, or pembrolizumab at established schedules. Part 2 dose expansion administers VVD-130037 at the recommended dose for expansion RDE, alone or in combination, to further evaluate safety and activity. Treatment cycles vary by combination, with docetaxel given every 3 weeks and paclitaxel given on days 1, 8, and 15 of each cycle. Participants undergo regular assessments including monitoring for dose-limiting toxicities during the first treatment cycle and tracking adverse events over up to 4 years. Laboratory tests, electrocardiograms, and imaging evaluations measure drug concentrations, heart rhythm, and tumor response. Researchers also evaluate overall response rates, duration of response, progression-free survival, and disease control rates. Safety follow-up and detailed pharmacokinetic studies are part of the long-term observation to understand the effects of VVD-130037 and its combinations.
CONDITIONS
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
V
Vividion Clinical Trial Call Center
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Vividion Therapeutics, Inc.
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | VVD-130037, alone and in combination, as studied in the trial | Guideline-recommended systemic chemotherapy (standard of care) |
|---|---|---|
| What it is | An experimental oral small molecule, VVD-130037, tested alone and with docetaxel, paclitaxel, or pembrolizumab in adults with advanced solid tumors after progression on standard therapies. | Established guideline-recommended intravenous chemotherapies for advanced solid tumors, typically using docetaxel, paclitaxel, or platinum-based regimens as initial systemic therapy. |
| Role in study or typical context | Evaluated for safety, tolerability, and initial efficacy in adults who have exhausted all standard systemic therapies. | Used before investigational enrollment, systemic chemotherapy is the foundation of routine treatment for eligible patients with advanced disease. |
| Primary use or intent | To determine the maximum tolerated dose, safety, and possible preliminary anti-tumor activity of VVD-130037 alone and in combination. | To provide established, evidence-based anti-cancer effects and symptom reduction in advanced/metastatic solid tumors. |
| How it is given or performed | VVD-130037 is given as oral tablets, either alone or together with intravenous docetaxel, paclitaxel, or pembrolizumab. Administration is per study protocol in sequential enrollment cohorts. | Standard-of-care taxane (docetaxel/paclitaxel) or platinum-based chemotherapy is given by intravenous infusion on established dosing schedules. |
| Evidence maturity and status | Evidence is limited to early-phase clinical investigation, with results from this trial not yet available and no established clinical outcomes. | Supported by extensive clinical evidence and decades of research in multiple tumor types. |
| Important limitations | Currently limited to first-in-human clinical experience. Safety profile, recommended dose, and effectiveness are not yet determined. Design includes multiple dose levels, combinations, and eligibility exclusions for patients with certain genetic mutations or comorbidities. | Not all tumors respond to standard chemotherapy, and treatment is often associated with significant side effects and toxicity. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Repeated 21-day or 28-day cycles until disease progression or discontinuation
Participants receive VVD-130037 orally once or twice daily in 21-day or 28-day treatment cycles, either alone or in combination with docetaxel, paclitaxel, or pembrolizumab administered via intravenous infusion on a specified schedule depending on the combination therapy.
Visits occur every 3 weeks for docetaxel or pembrolizumab combinations; weekly visits on Days 1, 8, and 15 for paclitaxel combinations; and regular visits for single agent dosing
Duration - Up to approximately 4 years
Participants are monitored for safety, adverse events, and clinical laboratory abnormalities up to approximately 4 years after treatment.
Periodic visits for safety and response assessments
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
7
Have more questions? Get in touch with our team for quick support
Nilotpal Roy, Tine Wyseure, I-Chung Lo...
https://pubmed.ncbi.nlm.nih.gov/41417010/Vividion Therapeutics, Inc.
Lead Sponsor